Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Applicability of RPMI 2650 and Calu-3 cell models for evaluation of nasal formulations
ID
Sibinovska, Nadica
(
Author
),
ID
Žakelj, Simon
(
Author
),
ID
Trontelj, Jurij
(
Author
),
ID
Kristan, Katja
(
Author
)
PDF - Presentation file,
Download
(689,95 KB)
MD5: A79BDF1F302D32E68B3BFC348C76664A
URL - Source URL, Visit
https://www.mdpi.com/1999-4923/14/2/369
Image galllery
Abstract
The RPMI 2650 and Calu-3 cell lines have been previously evaluated as models of the nasal and airway epithelial barrier, and they have demonstrated the potential to be used in drug permeation studies. However, limited data exist on the utilization of these two cell models for the assessment of nasal formulations. In our study, we tested these cell lines for the evaluation of in vitro permeation of intranasally administered drugs having a local and systemic effect from different solution- and suspension-based formulations to observe how the effects of formulations reflect on the measured in vitro drug permeability. Both models were shown to be sufficiently discriminative and able to reveal the effect of formulation compositions on drug permeability, as they demonstrated differences in the in vitro drug permeation comparable to the in vivo bioavailability. Good correlation with the available bioavailability data was also established for a limited number of drugs formulated as intranasal solutions. The investigated cell lines can be applied to the evaluation of in vitro permeation of intranasally administered drugs with a local and systemic effect from solution- and suspension-based formulations.
Language:
English
Keywords:
RPMI 2650 cell line
,
Calu-3 cell line
,
nasal drug formulations
,
nasal epithelium
,
drug permeability
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2022
Number of pages:
19 str.
Numbering:
Vol. 14, iss. 2, art. 369
PID:
20.500.12556/RUL-137348
UDC:
615
ISSN on article:
1999-4923
DOI:
10.3390/pharmaceutics14020369
COBISS.SI-ID:
107048707
Publication date in RUL:
13.06.2022
Views:
722
Downloads:
106
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Pharmaceutics
Shortened title:
Pharmaceutics
Publisher:
MDPI
ISSN:
1999-4923
COBISS.SI-ID:
517949977
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
06.02.2022
Projects
Funder:
Other - Other funder or multiple funders
Funding programme:
Lek Pharmaceuticals, d.d., Sandoz Development Center Slovenia
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0189
Name:
Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih
Funder:
Other - Other funder or multiple funders
Funding programme:
Public Scholarship, Development, Disability and Maintenance Fund of the Republic of Slovenia
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back